Table 3.
Feasibility outcomes. Values are n (%) unless otherwise noted
| High Load | Low Load | |||
|---|---|---|---|---|
| with High TUT | with Low TUT | with High TUT | with Low TUT | |
| Session time duration in minutesa | 43.4 (12.2) | 39.0 (6.1) | 53.0 (7.3) | 37.1 (7.0) |
| Adherenceb | ||||
| Number of zoom sessions completed / 12 | 11 (92) | 9 (71) | 11 (92) | 10 (79) |
| Number of home sessions completed / 36 | 21 (58) | 18 (49) | 21 (58) | 25 (68) |
| Fidelity of exercise dose parameters in seated | ||||
| Time-under-tension | 5 (42) | 5 (42) | 6 (50) | 7 (58) |
| Volume | 7 (58) | 8 (67) | 8 (67) | 10 (83) |
| Load intensity | 6 (50) | 1 (8) | 8 (67) | 8 (67) |
| Fidelity of exercise dose parameters in standing | ||||
| Time-under-tension | 5 (42) | 3 (25) | 6 (50) | 6 (50) |
| Volume | 7 (58) | 7 (58) | 8 (67) | 7 (58) |
| Load intensity | 5 (42) | 4 (33) | 9 (75) | 7 (58) |
| No. of participants who reporting adverse event | 8 (67) | 8 (67) | 8 (67) | 6 (50) |
| Severity of adverse events c | ||||
| Mild | 4 (33) | 6 (50) | 8 (67) | 3 (25) |
| Moderate | 3 (25) | 2 (17) | 0 | 3 (25) |
| Severe | 1 (8) | 0 | 0 | 0 |
| Achilles related adverse events | 3 (25) | 4 (33) | 4 (33) | 4 (33) |
| Severity of Achilles related adverse events | ||||
| Mild | 3 (25) | 4 (33) | 4 (33) | 3 (25) |
| Moderate | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 |
| No. of participants who used co-interventions | 3 (25) | 2 (17) | 2 (17) | 4 (33) |
| No. of participants using paracetamol | 4 (33) | 5 (42) | 4 (33) | 6 (50) |
| Total paracetamol tablets used d | 16 (33) | 31 (33) | 33 (25) | 17 (25) |
Abbreviations: TUT time-under-tension. a Mean (SD); bMedian (percentage); c Mild: some discomfort noted but without disruption of daily life that goes within 24–28 h; Moderate: discomfort enough to affect/reduce normal activity that goes within 3-5 days; Severe: complete inability to perform daily activities and lead a normal life and that requires medical intervention; dtablet dose = 500 mg;